Background
Methods
Study design and ethical statement
NHIS-COVID-19 cohort database and study population
CRD
Endpoints
Data collection
Statistical analysis
Results
Study population
Variable | Number (%) | Mean (SD) |
---|---|---|
Age, year | ||
20–29 | 32,380 (26.0) | |
30–39 | 13,154 (10.6) | |
40–49 | 16,519 (13.3) | |
50–59 | 25,260 (20.3) | |
60–69 | 19,669 (15.8) | |
70–79 | 10,426 (8.4) | |
≥ 80 | 6922 (9.2) | |
Sex, male | 48,726 (39.2) | |
Residence | ||
Seoul | 8056 (6.5) | |
Gyeonggi-do | 81,493 (65.5) | |
Daegu | 6855 (5.5) | |
Gyeongsangbuk-do | 15,107 (12.2) | |
Other area | 12,819 (10.3) | |
Underlying disability | 7655 (6.2) | |
Income level | ||
Q1 (Lowest) | 32,387 (26.0) | |
Q2 | 24,979 (20.1) | |
Q3 | 27,774 (22.3) | |
Q4 (Highest) | 37,069 (29.8) | |
Unknown | 2121 (1.7) | |
Charlson comorbidity index | 1.8 (2.9) | |
Hypertension | 32,727 (26.3) | |
DM without chronic complication | 13,781 (11.1) | |
DM with chronic complication | 4255 (3.4) | |
Peripheral vascular disease | 7198 (5.8) | |
Renal disease | 1392 (1.1) | |
Rheumatic disease | 2958 (2.4) | |
Dementia | 3926 (3.2) | |
Peptic ulcer disease | 9872 (7.9) | |
Hemiplegia or paraplegia | 568 (0.5) | |
Moderate or severe liver disease | 146 (0.1) | |
Mild liver disease | 13,612 (10.9) | |
Cerebrovascular disease | 5763 (4.6) | |
Congestive heart failure | 3683 (3.0) | |
Myocardial infarction | 1187 (1.0) | |
Malignancy | 22,013 (17.7) | |
Metastatic solid tumor | 4072 (3.3) | |
AIDS/HIV | 32 (0.0) | |
Any chronic respiratory diseases | 36,365 (29.2) | |
COPD | 4488 (3.6) | |
Asthma | 33,858 (27.2) | |
Interstitial lung disease | 421 (0.3) | |
Lung cancer | 769 (0.6) | |
Lung disease d/t external agent | 437 (0.4) | |
Obstructive sleep apnea | 550 (0.4) | |
Tuberculosis of lung | 608 (0.5) |
Variable | CRD n = 36,365 | Control n = 87,965 | P value |
---|---|---|---|
Age, year | < 0.001 | ||
20–29 | 6932 (19.1) | 25,448 (28.9) | |
30–39 | 3451 (9.5) | 9703 (11.0) | |
40–49 | 4503 (12.4) | 12,016 (13.7) | |
50–59 | 6787 (18.7) | 18,473 (21.0) | |
60–69 | 6806 (18.7) | 12,863 (14.6) | |
70–79 | 4534 (12.5) | 5892 (6.7) | |
≥ 80 | 3352 (9.2) | 3570 (4.1) | |
Sex, male | 36,228 (41.2) | 12,498 (34.4) | < 0.001 |
Residence | < 0.001 | ||
Seoul | 2367 ( 6.5) | 5689 ( 6.5) | |
Gyeonggi-do | 23,442 (64.5) | 58,051 (66.0) | |
Daegu | 2088 ( 5.7) | 4767 ( 5.4) | |
Gyeongsangbuk-do | 4716 (13.0) | 10,391 (11.8) | |
Other area | 3752 (10.3) | 9067 (10.3) | |
Underlying disability | 3109 (8.5) | 4546 (5.2) | < 0.001 |
Income level | < 0.001 | ||
Q1 (Lowest) | 9758 (26.8) | 22,629 (25.7) | |
Q2 | 6681 (18.4) | 18,298 (20.8) | |
Q3 | 7815 (21.5) | 19,959 (22.7) | |
Q4 (Highest) | 11,492 (31.6) | 25,577 (29.1) | |
Unknown | 619 (1.7) | 1502 ( 1.7) | |
Charlson comorbidity index | 2.7 (3.3) | 1.5 (2.6) | < 0.001 |
Hypertension | 12,896 (35.5) | 19,831 (22.5) | < 0.001 |
DM without chronic complication | 5676 (15.6) | 8105 ( 9.2) | < 0.001 |
DM with chronic complication | 1897 ( 5.2) | 2358 ( 2.7) | < 0.001 |
Peripheral vascular disease | 3306 ( 9.1) | 3892 ( 4.4) | < 0.001 |
Renal disease | 663 ( 1.8) | 729 ( 0.8) | < 0.001 |
Rheumatic disease | 1325 ( 3.6) | 1633 ( 1.9) | < 0.001 |
Dementia | 1940 ( 5.3) | 1986 ( 2.3) | < 0.001 |
Peptic ulcer disease | 4397 (12.1) | 5475 ( 6.2) | < 0.001 |
Hemiplegia or paraplegia | 255 ( 0.7) | 313 ( 0.4) | < 0.001 |
Moderate or severe liver disease | 58 ( 0.2) | 88 ( 0.1) | 0.007 |
Mild liver disease | 5546 (15.3) | 8066 ( 9.2) | < 0.001 |
Cerebrovascular disease | 2635 ( 7.2) | 3128 ( 3.6) | < 0.001 |
Congestive heart failure | 1905 ( 5.2) | 1778 ( 2.0) | < 0.001 |
Myocardial infarction | 554 ( 1.5) | 633 ( 0.7) | < 0.001 |
Malignancy | 8859 (24.4) | 13,154 (15.0) | < 0.001 |
Metastatic solid tumor | 1886 ( 5.2) | 2186 ( 2.5) | < 0.001 |
AIDS/HIV | 12 ( 0.0) | 20 ( 0.0) | 0.405 |
Risk of COVID-19 in South Korea
Variable | Multivariable model | P-value |
---|---|---|
OR (95% CI) | ||
Chronic respiratory diseases group (model1) | 1.04 (0.99, 1.09) | 0.156 |
Chronic respiratory diseases: sensitivity analyses (model2) | ||
COPD | 0.96 (0.85, 1.09) | 0.553 |
Asthma | 1.01 (0.96, 1.07) | 0.464 |
Interstitial lung disease | 1.63 (1.17, 2.26) | 0.004 |
Lung cancer | 0.91 (0.67, 1.23) | 0.533 |
Lung disease d/t external agent | 1.35 (0.99, 1.85) | 0.061 |
Obstructive sleep apnea | 1.65 (1.23, 2.16) | < 0.001 |
Tuberculosis of lung | 0.92 (0.75, 1.11) | 0.372 |
Age, year | ||
20–29 | 1 | |
30–39 | 0.94 (0.86, 1.02) | 0.153 |
40–49 | 0.86 (0.80, 0.93) | < 0.001 |
50–59 | 0.74 (0.69, 0.79) | < 0.001 |
60–69 | 0.60 (0.55, 0.66) | < 0.001 |
70–79 | 0.47 (0.42, 0.52) | < 0.001 |
≥ 80 | 0.38 (0.33, 0.44) | < 0.001 |
Income level | ||
Q1 (Lowest) | 1 | |
Q2 | 0.80 (0.75, 0.86) | < 0.001 |
Q3 | 0.78 (0.73, 0.83) | < 0.001 |
Q4 (Highest) | 0.83 (0.78, 0.88) | < 0.001 |
Unknown | 0.75 (0.62, 0.91) | 0.004 |
Sex, male | 1.01 (0.96, 1.06) | 0.678 |
Residence | ||
Seoul | 1 | |
Gyeonggi-do | 0.90 (0.82, 0.99) | 0.038 |
Daegu | 0.96 (0.84, 1.10) | 0.562 |
Gyeongsangbuk-do | 0.94 (0.84, 1.05) | 0.271 |
Other area | 0.89 (0.79, 1.00) | 0.053 |
Underlying disability | 1.11 (1.00, 1.22) | 0.041 |
Charlson comorbidity index (model 2) | 1.19 (1.18, 1.20) | < 0.0001 |
Hypertension | 0.80 (0.74, 0.85) | < 0.001 |
DM without chronic complication | 1.75 (1.63, 1.88) | < 0.001 |
DM with chronic complication | 0.81 (0.71, 0.92) | 0.001 |
Peripheral vascular disease | 0.75 (0.67, 0.83) | < 0.001 |
Renal disease | 0.91 (0.75, 1.11) | 0.371 |
Rheumatic disease | 0.98 (0.85, 1.12) | 0.734 |
Dementia | 1.96 (1.72, 2.22) | < 0.001 |
Peptic ulcer disease | 1.48 (1.37, 1.59) | < 0.001 |
Hemiplegia or paraplegia | 2.69 (2.11, 3.44) | < 0.001 |
Moderate or severe liver disease | 0.59 (0.33, 1.06) | 0.076 |
Mild liver disease | 2.12 (1.99, 2.27) | < 0.001 |
Cerebrovascular disease | 0.99 (0.88, 1.11) | 0.886 |
Congestive heart failure | 2.88 (2.60, 3.19) | < 0.001 |
Myocardial infarction | 4.55 (3.95, 5.24) | < 0.001 |
Malignancy | 2.04 (1.93, 2.15) | < 0.001 |
Metastatic solid tumor | 0.95 (0.84, 1.07) | 0.387 |
AIDS/HIV | 4.21 (1.84, 9.64) | < 0.001 |
Hospital mortality among patients with COVID-19
Variable | Multivariable model | P-value |
---|---|---|
OR (95% CI) | ||
Chronic respiratory diseases (model 1) | 1.19 (0.86, 1.64) | 0.299 |
Chronic respiratory diseases: sensitivity analyses (model 2) | ||
COPD | 1.56 (1.06, 2.2) | 0.024 |
Asthma | 1.03 (0.76, 1.41) | 0.834 |
Interstitial lung disease | 1.83 (0.74, 4.55) | 0.193 |
Lung cancer | 1.82 (0.80, 4.14) | 0.154 |
Lung disease d/t external agent | 3.54 (1.70, 7.38) | < 0.001 |
Obstructive sleep apnea | 0.47 (0.06, 3.94) | 0.486 |
Tuberculosis of lung | 1.65 (0.48, 5.64) | 0.423 |
Age, 10 year increase | 2.85 (2.40, 3.38) | < 0.001 |
Income level | ||
Q1 (Lowest) | 1 | |
Q2 | 0.96 (0.59, 1.57) | 0.882 |
Q3 | 1.08 (0.70, 1.65) | 0.739 |
Q4 (Highest) | 0.89 (0.652, 1.30) | 0.554 |
Unknown | 0.67 (0.18, 2.54) | 0.560 |
Sex, male | 2.12 (1.55, 2.88) | < 0.001 |
Residence | ||
Seoul | 1 | |
Gyeonggi-do | 2.26 (0.75, 6.86) | 0.148 |
Daegu | 2.60 (0.74, 9.16) | 0.136 |
Gyeongsangbuk-do | 2.40 (0.77, 7.49) | 0.133 |
Other area | 1.69 (0.50, 5.72) | 0.401 |
Underlying disability | 1.33 (0.94, 1.89) | 0.109 |
Charlson comorbidity index, model 2 | 1.80 (1.32, 2.44) | < 0.001 |
Hypertension | 1.36 (0.89, 2.06) | 0.153 |
DM without chronic complication | 1.87 (1.35, 2.59) | < 0.001 |
DM with chronic complication | 1.61 (1.06, 2.45) | 0.027 |
Peripheral vascular disease | 1.19 (0.81, 1.76) | 0.76 |
Renal disease | 1.47 (0.87, 2.47) | 0.148 |
Rheumatic disease | 0.58 (0.30, 1.12) | 0.107 |
Dementia | 1.61 (1.11, 2.32) | 0.011 |
Peptic ulcer disease | 1.04 (0.73, 1.49) | 0.818 |
Hemiplegia or paraplegia | 1.92 (1.03, 3.59) | 0.040 |
Moderate or severe liver disease | 5.12 (1.32, 19.90) | 0.018 |
Mild liver disease | 0.80 (0.58, 1.10) | 0.170 |
Cerebrovascular disease | 0.57 (0.38, 0.87) | 0.009 |
Congestive heart failure | 1.91 (1.38, 2.66) | < 0.001 |
Myocardial infarction | 0.79 (0.47, 1.33) | 0.374 |
Malignancy | 1.07 (0.78, 1.46) | 0.694 |
Metastatic solid tumor | 1.37 (0.85, 2.19) | 0.192 |
AIDS/HIV | 1.43 (0.11, 19.37) | 0.788 |